Immunovant Balance Sheet
NASDAQ: IMVTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Immunovant financial position
At the end of fiscal 2026, Immunovant reported total assets of $957.0 million, up 23.3% from a year earlier against total liabilities of $104.4 million. Shareholders' equity stood at $852.6 million, or 89.1% of assets. The company held $902.1 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 9.09, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Immunovant balance sheet (annual)
| Fiscal year (USD) | FY 20262026-03-31 | FY 20252025-03-31 | FY 20242024-03-31 | FY 20232023-03-31 | FY 20222022-03-31 | FY 20202021-03-31 | FY 20192020-03-31 | FY 20192019-03-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 902.11M | 713.97M | 635.37M | 376.53M | 493.82M | 400.15M | 100.57M | 6.99M |
| Receivables | 1.13M | 2.08M | 5.34M | 700.00K | 12.23M | 596.00K | — | — |
| Total Current Assets | 948.82M | 767.66M | 665.77M | 404.33M | 512.93M | 409.01M | 109.08M | 12.58M |
| Property, Plant & Equipment | 443.00K | 844.00K | 462.00K | 333.00K | 330.00K | 201.00K | 65.00K | 54.00K |
| Total Assets | 957.01M | 776.22M | 666.37M | 405.84M | 515.56M | 412.49M | 109.39M | 13.83M |
| Accounts Payable | 7.54M | 17.66M | 7.16M | 1.35M | 18.63M | 2.43M | 1.19M | 206.00K |
| Total Current Liabilities | 104.42M | 68.78M | 48.61M | 43.30M | 44.52M | 18.77M | 15.32M | 300.45K |
| Total Liabilities | 104.42M | 68.78M | 48.61M | 43.34M | 45.74M | 21.01M | 15.32M | 6.49M |
| Shareholders' Equity | 852.59M | 707.45M | 617.76M | 362.49M | 469.82M | 391.48M | 94.07M | 7.34M |
| Retained Earnings | -1.75B | -1.24B | -825.68M | -566.35M | -355.39M | -198.66M | -91.23M | -24.84M |
| Net Cash (Debt) | 902.11M | 713.97M | 635.37M | 376.53M | 493.82M | 400.15M | 100.57M | 6.99M |
| Shares Outstanding | 203.94M | 170.11M | 145.58M | 130.33M | 116.48M | 97.97M | 54.66M | 38.59M |
This table shows 8 annual periods of Immunovant's balance sheet, from FY 2026 back to FY 2019, across 12 line items including cash & equivalents, receivables, total current assets. Values in USD; B = billions, M = millions. Fiscal periods follow IMVT's reporting calendar. What is a balance sheet?